Authors
Latest:
Dr Gay on Efficacy Findings From the IsKia Trial in Multiple MyelomaFrancesca Gay, MD, PhD, discusses the safety and efficacy findings derived from the phase 3 IsKia trial in patients with newly diagnosed multiple myeloma.
Latest:
Dr. Francesco Lo-Coco on Arsenic Trioxide in APLFrancesco Lo-Coco, MD, Hematology, University Tor Vergata, discusses a new emerging treatment, arsenic trioxide (ATO), in acute promyelocytic leukemia (APL).
Latest:
Dr Foss on the FDA Approval of Denileukin Diftitox for CTCLFrancine Foss, MD, discusses the FDA approval of denileukin diftitox for the treatment of patients with CTCL.
Latest:
Racial/Ethnic and Age Disparities in Chemotherapy Selection for Colorectal CancerStudies have evaluated racial/ethnic and age disparities in whether patients receive chemotherapy for nonmetastatic colo-rectal cancer
Latest:
ASH Interview SeriesThe December issue of Oncology & Biotech News featured highlights from the 51st American Society of Hematology (ASH) Annual Meeting and Exposition. We wrap up our ASH coverage this month with interviews on multiple myeloma with Brian G.M. Durie, MD, medical director and co-founder of the International Myeloma Foundation; chronic lymphocytic leukemia (CLL) with Robert J. Kreitman, MD, from the National Cancer Institute; and chronic myeloid leukemia (CML) with Francis J. Giles, MD, Cancer Therapy and Research Center at The University of Texas Health Science Center in San Antonio.
Latest:
Sequencing Throughout Multiple Lines of Therapy in RR DTCBefore closing out their discussion on RR DTC management, panelists consider the advent of sequencing through multiple lines of therapy.
Latest:
Dr. Yao on Transplants Beyond Milan Criteria for Liver CancerFrancis Yao, MD, gastroenterologist and medical director of the Liver Transplant Program at the University of California San Francisco Medical Center, discusses liver transplants beyond Milan criteria for patients with liver cancer.
Latest:
Dr. Cervantes Discusses COMFORT-II Long-Term DataFrancisco Cervantes, MD, PhD, Hospital Clinic, IDIBAPS, Barcelona, Spain, discusses the initial and long-term findings of the COMFORT-II trial of ruxolitib for the treatment of myelofibrosis.
Latest:
Dr Esteva on the Impact of the MAINTAIN Trial in HR+/HER2– Breast CancerFrancisco J. Esteva, MD, PhD, discusses the impact of the phase 2 MAINTAIN study of treatment with ribociclib following progression on CDK4/6 inhibition in patients with hormone receptor-positive, HER2-negative breast cancer.
Latest:
Dr Esteva on the monarchE and NATALEE Trials in HR+/HER2– Breast CancerFrancisco J. Esteva, MD, PhD, discusses the phase 3 monarchE and NATALEE trials in patients with hormone receptor–positive/HER2-negative breast cancer.
Latest:
Dr. Marty on Letermovir for CMV Prevention After Stem Cell TransplantFrancisco Marty, MD, Dana-Farber Cancer Institute, discusses the initial results of the Phase III trial evaluating letermovir for CMV after bone marrow transplant.
Latest:
Integrating PARP Inhibitors Into the Treatment of WomenAfter years in development, several PARP inhibitors have achieved indications in ovarian cancer treatment, while others continue in development and expanding indications.
Latest:
Dr. Muggia on Targeted Therapies for Ovarian CancerFranco M. Muggia, MD, PhD, professor, Department of Medicine, NYU Langone Medical Center, discusses targeted therapies for patients with ovarian cancer.
Latest:
Dr. Muggia on Current Status of Intraperitoneal Therapy for Gynecologic CancersFranco Muggia, MD, professor of Medicine, NYU Langone Medical Center, discusses the current status of intraperitoneal therapy for patients with gynecologic malignancies.
Latest:
Dr. Bidard on the FDA Approval of Elacestrant in ER+/HER2– Metastatic Breast CancerFrançois-Clément Bidard, MD PhD, discusses the significance of the FDA approval of elacestrant in patients with estrogen receptor–positive, HER2-negative metastatic breast cancer and key efficacy and safety data from the phase 3 EMERALD trial.
Latest:
Racial/Ethnic and Age Disparities in Chemotherapy Selection for Colorectal CancerStudies have evaluated racial/ethnic and age disparities in whether patients receive chemotherapy for nonmetastatic colo-rectal cancer
Latest:
Erythrocytes Used as Tumor Antigen Delivery SystemFrançoise Horand, director, R&D Operations, Erytech Pharma, discusses a study investigating the use of erythrocytes as a tumor antigen delivery system to target antigen-presenting cells and induce efficient immune response against tumors.
Latest:
Dr. Sinicrope on Mismatch Repair-Deficient Patients With Metastatic Colorectal CancerFrank A. Sinicrope, MD, medical oncologist, Departments of Gastroenterology and Hepatology and Oncology, Mayo Clinic, discusses patients with metastatic colorectal cancer (mCRC) who are mismatch repair-deficient.
Latest:
Dr. Vicini on the Potential Utility of the DCISionRT Test in HER2+ DCIS of the BreastFrank A. Vicini, MD, discusses the potential utility of using the DCISionRT test to determine treatment benefit in the phase 3 NRG-NSABP-B43 trial in HER2-positive ductal carcinoma in situ of the breast.
Latest:
Frank delaRama on Patient Education in Prostate CancerFrank delaRama, RN, MS, AOCNS®, from the Palo Alto Medical Foundation, explains the role of oncology nurse navigators in providing relevant information to men with prostate cancer.
Latest:
Dr. Mott on Sequencing of Treatments with NSCLCFrank E. Mott, MD, associate professor, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the sequencing of treatments for patients with non-small cell lung cancer (NSCLC).
Latest:
Dr. Mott Discusses Targeted Therapy for ALK+ NSCLCFrank E. Mott, MD, FACP, department of Thoracic Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses taregeted therapy for ALK-positive non-small cell lung cancer (NSCLC).
Latest:
Argumentum Ad Populum: Medical Wikis 101What exactly is a medical wiki, and for that matter, a wiki in general? Are these resources useful to you and your patients?
Latest:
Hypofractionated and Stereotactic Body Radiotherapy in Prostate CancerDespite limited data comparing stereotactic body radiation therapy to standard or hypofractionated radiotherapy with regards to long-term clinical outcomes and toxicity profiles, the data are promising and appropriately selected patients can be offered such an approach off-protocol.
Latest:
Dr. Holmes on Neoadjuvant Endocrine Therapy in Breast CancerFrankie Ann Holmes, MD, a physician at Texas Oncology, discusses neoadjuvant endocrine therapy for patients with breast cancer.
Latest:
Dr. Kass on Optimal Treatment Sequencing in HER2-Positive Breast CancerFred C. Kass, MD, oncology/hematology, internal medicine, Cancer Center of Santa Barbara, discusses challenges associated with optimal treatment sequencing for patients with HER2-positive breast cancer.
Latest:
TechSectors: Connectivity: Improving Physician-Patient CommunicationMore than ever before, healthcare professionals are strapped for time.
